
Actuate Therapeutics Inc (ACTU) Market Cap
Actuate Therapeutics Inc has a market capitalization of $65.9M.
Financials based on reported quarter end 2025-12-31
Price: $2.78
โฒ 0.52 (22.74%)
Market Cap: 65.91M
NASDAQ ยท time unavailable
CEO: Daniel Schmitt
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2024-08-13
Website: https://actuatetherapeutics.com
Actuate Therapeutics Inc (ACTU) - Company Information
Market Cap: 65.91M ยท Sector: Healthcare
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Analyst Sentiment
Based on 1 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 1 sources)
Consensus Price Target
Low
$21
Median
$21
High
$21
Average
$21
Potential Upside: 655.4%
Price & Moving Averages
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"ACTU reported revenue of $0 and net income of -$4.6m (EPS: -$0.20) for the quarter ended 2025-12-31. Net margin was negative, and operating cash flow was -$3.7m, producing free cash flow of -$3.7m. Balance sheet figures show total assets of $14.0m versus total liabilities of $6.1m, leaving equity of $7.9m. Net debt is negative (-$12.8m), indicating the company is in a net cash position rather than levered debt. From a cash-flow quality perspective, results are currently dominated by cash burn: operating cash flow and free cash flow are both materially negative, and dividends are $0. With no buyback information provided, shareholder returns are primarily tied to share price performance, which has been weak: the stock is down -71.0% over 1 year and -62.0% YTD, suggesting the market has continued to reassess prospects. Valuation context is limited because market cap and revenue are not provided, and the company is loss-making, so P/E and FCF yield cannot be meaningfully assessed from the supplied inputs. Analyst price targets cluster at $21, but the current price of $2.29 implies the market price is far below those targets."
Revenue Growth
Revenue is reported as $0 for the period, preventing assessment of growth or demand drivers.
Profitability
Net income is -$4.6m with EPS of -$0.20, indicating sustained losses and no evidence of operating profitability in the provided quarter.
Cash Flow Quality
Operating cash flow of -$3.7m and free cash flow of -$3.7m point to ongoing cash burn; dividends are $0 and no buybacks are provided.
Leverage & Balance Sheet
Net debt is -$12.8m (net cash position). Assets of $14.0m exceed liabilities of $6.1m, with equity of $7.9m supporting resilience despite losses.
Shareholder Returns
Total shareholder return appears weak given large capital depreciation: -71% 1-year and -66% 6-month declines, with no dividends and no buyback data to offset price weakness.
Analyst Sentiment & Valuation
Consensus price target is $21 versus a current price of $2.29, but the company is loss-making with revenue shown as $0, limiting traditional valuation interpretation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.





